Skip to main content

Detroit R&D Secures $1.2 Million in SBIR Grants

NEW YORK, Nov. 10 (GenomeWeb News) - Detroit R&D said today that it has received $1.2 million in new phase I and phase II SBIR grants, which will support the company's continued genomic and proteomic research into xenobiotic and toxic substances metabolism.


The first phase I grant will provide $100,000 to support of the development of antibody chips to screen drug-metabolizing enzymes, said Detroit R&D. The second phase I grant is for $400,000, and will be used to find markers for fetal alcohol syndrome.


Detroit R&D said that the phase II grant, worth $750,000, was awarded to help in the development of frog embryo DNA microarrays as a tool for toxicogenomic studies.



The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.